(Reuters) - AbbVie Inc (ABBV.N) is to buy Pharmacyclics Inc (PCYC.O) for about $21 billion (14 billion pounds), giving it access to what is expected to be one of the world's top-selling cancer drugs ...

- Adds Imbruvica® a first in class BTK inhibitor approved in multiple indications for blood cancers. - Extensive clinical program with over 50 studies ongoing evaluating Imbruvica® as a treatment for ...

Pharmacyclics is already up 150% over the past 12 months, giving it a whopping trailing P/E of 120. The approval of Imbruvica for MCL only unlocks half of its sales potential -- investors are waiting ...

SUNNYVALE, Calif. (AP) -- Pharmacyclics is getting a priority review of its blood cancer treatment by federal regulators. A priority review shortens a drug evaluation by the Food and Drug ...

Winning an apparent bidding war, drug maker Abbvie (ABBV) said Wednesday night it will pay $21 billion for biotech firm Pharmacyclics, the maker of the promising cancer drug Imbruvica that some say ...

Apollo Global's Josh Harris made a fortune buying the tumbling debt of LyondellBasell during the credit crunch and taking control of the chemical giant in bankruptcy, Warren Buffett cut his ...

AbbVie shares sank Thursday after the US pharmaceutical firm announced it will buy leukemia drug maker Pharmacyclics in a $21 billion deal. AbbVie and Pharmacyclics said in a statement late Wednesday ...

What: Shares of Pharmacyclics (NASDAQ: PCYC), a biopharmaceutical company developing small-molecule therapies to treat cancer and other immune-mediated diseases, dipped as much as 12% after reporting ...

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE ™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who ...